Talzenna (talazoparib) vs Truqap (capivasertib)

Talzenna (talazoparib) and Truqap (capivasertib) are targeted therapies but they act on different pathways within cancer cells. Talzenna is a PARP inhibitor used primarily in the treatment of certain types of breast cancer with a specific genetic mutation (BRCA), and it works by preventing cancer cells from repairing their DNA, leading to cell death. Truqap, on the other hand, is an AKT inhibitor that interferes with a signaling pathway involved in cell growth and survival, and while it's being studied in various cancers, its use is not yet approved as of the last available data. Patients should consult with their healthcare provider to determine which medication is appropriate for their specific cancer type and genetic profile.

Difference between Talzenna and Truqap

Metric	Talzenna (talazoparib)	Truqap (capivasertib)
Generic name	talazoparib	capivasertib
Indications	BRCA-mutated HER2-negative locally advanced or metastatic breast cancer	Currently being investigated for treatment in various cancers including breast cancer, prostate cancer, and lung cancer in clinical trials
Mechanism of action	Poly (ADP-ribose) polymerase (PARP) inhibitor	AKT protein kinase inhibitor
Brand names	Talzenna	Truqap (as of the knowledge cutoff date, not commercially available; may be a hypothetical or investigational name)
Administrative route	Oral	Oral (assumed based on available information)
Side effects	Anemia, neutropenia, thrombocytopenia, fatigue, headache, vomiting, alopecia, etc.	Hyperglycemia, rash, diarrhea, fatigue, nausea, etc. (based on phase I/II clinical trial data)
Contraindications	Known hypersensitivity to talazoparib or any of its excipients	Not fully established; would include known hypersensitivity to capivasertib or its excipients
Drug class	PARP inhibitor	AKT inhibitor
Manufacturer	Pfizer	AstraZeneca (as of the knowledge cutoff date, capivasertib is under clinical development by AstraZeneca)

Efficacy

Talzenna (talazoparib) Efficacy in Breast Cancer

Talzenna (talazoparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Patients are selected for therapy based on an FDA-approved companion diagnostic for talazoparib. The efficacy of Talzenna for this indication was demonstrated in the EMBRACA trial, a randomized, open-label study comparing talazoparib to standard chemotherapy. Patients treated with Talzenna showed a statistically significant improvement in progression-free survival (PFS) compared to those who received chemotherapy. This improvement in PFS indicates that Talzenna can effectively delay the progression of BRCA-mutated breast cancer.

Furthermore, in the EMBRACA trial, the objective response rate (ORR) was higher in the talazoparib arm compared to the chemotherapy arm. This suggests that Talzenna is not only capable of delaying disease progression but also has a higher likelihood of reducing tumor size. However, it is important to note that overall survival (OS) data was immature at the time of the final PFS analysis, and therefore conclusions regarding the impact of Talzenna on overall survival in breast cancer patients cannot be definitively made without further data.

Capivasertib (Truqap) Efficacy in Breast Cancer

Capivasertib (Truqap) is an investigational drug that is not yet approved for any indication as of the knowledge cutoff date in 2023. However, it has been studied in clinical trials for its potential use in treating breast cancer. Capivasertib is an AKT inhibitor, and its efficacy has been explored in combination with other cancer therapies in patients with advanced breast cancer. In clinical studies, such as the FAKTION trial, capivasertib in combination with fulvestrant demonstrated an improvement in progression-free survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer who had progressed on prior endocrine therapy.

While the results from clinical trials are promising, it is important to note that capivasertib (Truqap) is still undergoing investigation and has not yet received regulatory approval for the treatment of breast cancer. The data from ongoing trials will continue to inform the safety and efficacy profile of capivasertib for potential future use in breast cancer treatment. Until then, its use remains experimental and confined to the context of clinical trials.

Regulatory Agency Approvals

Talzenna

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Truqap

Food and Drug Administration (FDA), USA

Access Talzenna or Truqap today

If Talzenna or Truqap are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Talzenna

Buy Truqap

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: